- Home
- BMEA vs KNDI Comparison
BMEA vs KNDI Comparison
Compare BMEA & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- KNDI
- Stock Information
- Founded
- BMEA 2017
- KNDI 2002
- Country
- BMEA United States
- KNDI China
- Employees
- BMEA N/A
- KNDI N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- KNDI Auto Manufacturing
- Sector
- BMEA Health Care
- KNDI Consumer Discretionary
- Exchange
- BMEA Nasdaq
- KNDI Nasdaq
- Market Cap
- BMEA 114.3M
- KNDI 109.2M
- IPO Year
- BMEA 2021
- KNDI N/A
- Fundamental
- Price
- BMEA $1.93
- KNDI $1.37
- Analyst Decision
- BMEA Strong Buy
- KNDI
- Analyst Count
- BMEA 10
- KNDI 0
- Target Price
- BMEA $15.70
- KNDI N/A
- AVG Volume (30 Days)
- BMEA 559.5K
- KNDI 249.5K
- Earning Date
- BMEA 10-28-2025
- KNDI 08-19-2025
- Dividend Yield
- BMEA N/A
- KNDI N/A
- EPS Growth
- BMEA N/A
- KNDI N/A
- EPS
- BMEA N/A
- KNDI N/A
- Revenue
- BMEA N/A
- KNDI $104,035,613.00
- Revenue This Year
- BMEA N/A
- KNDI N/A
- Revenue Next Year
- BMEA N/A
- KNDI N/A
- P/E Ratio
- BMEA N/A
- KNDI N/A
- Revenue Growth
- BMEA N/A
- KNDI N/A
- 52 Week Low
- BMEA $1.29
- KNDI $0.89
- 52 Week High
- BMEA $13.07
- KNDI $2.07
- Technical
- Relative Strength Index (RSI)
- BMEA 55.47
- KNDI 48.40
- Support Level
- BMEA $1.77
- KNDI $1.34
- Resistance Level
- BMEA $2.08
- KNDI $1.45
- Average True Range (ATR)
- BMEA 0.11
- KNDI 0.08
- MACD
- BMEA 0.01
- KNDI -0.02
- Stochastic Oscillator
- BMEA 51.61
- KNDI 10.71
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.